Mutations in the Nucleotide-Binding Sites of P-Glycoprotein That Affect Substrate Specificity Modulate Substrate-Induced Adenosine Triphosphatase Activity
- 1 June 1998
- journal article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 37 (25) , 9073-9082
- https://doi.org/10.1021/bi972656j
Abstract
The amino- and carboxy-terminal nucleotide-binding domains (NBD1 and NBD2) of P-glycoprotein (P-gp) share over 80% sequence identity. Almost all of NBD1 can be exchanged by corresponding NBD2 segments with no significant loss of function, except for a small segment around the Walker B motif. Within this segment, we identified two sets of residues [ERGA → DKGT (522−525) and T578C] that, when replaced by their NBD2 counterparts, cause dramatic alterations of the substrate specificity of the protein [Beaudet, L., and Gros, P. (1995) J. Biol. Chem. 270, 17159−17170]. We wished to gain insight into the molecular basis of this defect. For this, we overexpressed the wild-type mouse Mdr3 and variants bearing single or double mutations at these positions in the yeast Pichia pastoris. P-gp-specific ATPase activity was measured in yeast plasma membrane preparations after detergent solubilization and reconstitution in Escherichia coli proteoliposomes. P-gp proteoliposomes from P. pastoris showed a strong verapamil- and valinomycin-stimulated ATPase activity, with characteristics (KM, Vmax) similar to those measured in mammalian cells. Mutations did not appear to affect the KM for Mg2+ATP (∼ 0.4 mM), but maximum velocity (Vmax) of the drug-stimulated ATPase activity was severely affected in a substrate/modulator-specific fashion. Indeed, all mutants showed complete loss of verapamil-induced ATPase, while all retained at least some degree of valinomycin-induced ATPase activity. Photolabeling studies with [125I]iodoarylazidoprazosin, including competition with MDR drugs and modulators, suggested that drug binding was not affected in the mutants. The altered drug resistance profiles of the ERGA → DKGT(522−525) and T578C mutants in vivo, together with the observed alterations in substrate-induced ATPase activity of these proteins, suggest that the residues involved may form part of a signal pathway between the membrane regions (substrate binding) and the ATP binding sites.Keywords
This publication has 13 references indexed in Scilit:
- Inorganic and organic phosphate measurements in the nanomolar rangePublished by Elsevier ,2004
- A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificityEuropean Journal of Immunology, 1996
- Transmembrane Organization of Mouse P-glycoprotein Determined by Epitope Insertion and ImmunofluorescencePublished by Elsevier ,1996
- Characterization and Analysis of Conserved Motifs in a Peroxisomal ATP-binding Cassette TransporterJournal of Biological Chemistry, 1996
- Functional Dissection of P-glycoprotein Nucleotide-binding Domains in Chimeric and Mutant ProteinsPublished by Elsevier ,1995
- Drug-stimulated ATPase activity of the human P-glycoproteinJournal of Bioenergetics and Biomembranes, 1995
- Using purified P-glycoprotein to understand multidrug resistanceJournal of Bioenergetics and Biomembranes, 1995
- The human MDR3 P‐glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic miceFEBS Letters, 1994
- Assessing hydrophobic regions of the plasma membrane H+-ATPase from Saccharomyces cerevisiaeBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1992
- Measurement of protein using bicinchoninic acidAnalytical Biochemistry, 1985